LIGAND PHARMACEUTICALS INC Insider Trading for September 2018
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LIGAND PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in LIGAND PHARMACEUTICALS INC for September 2018.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 27 2018 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | J | 0.00 | 1,916,509 | 0 | 0 | |
| Sep 27 2018 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | J | 0.00 | 38,630 | 0 | 1,916,509 | |
| Sep 27 2018 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Sell | S | 19.15 | 262,881 | 5,034,250 | 6,038,083 | 6.3 M to 6 M (-4.17 %) |
| Sep 18 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Option Exercise | M | 100.38 | 2,813 | 282,369 | 6,830 | |
| Sep 18 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Sell | S | 250.69 | 2,813 | 705,181 | 27,763 | 30.6 K to 27.8 K (-9.20 %) |
| Sep 18 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Buy | M | 100.38 | 2,813 | 282,369 | 30,576 | 27.8 K to 30.6 K (+10.13 %) |
| Sep 06 2018 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Option Exercise | M | 17.88 | 2,500 | 44,700 | 0 | |
| Sep 06 2018 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Option Exercise | M | 8.58 | 2,500 | 21,450 | 0 | |
| Sep 06 2018 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Sell | S | 255.05 | 5,000 | 1,275,250 | 26,856 | 31.9 K to 26.9 K (-15.70 %) |
| Sep 06 2018 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Buy | M | 17.88 | 2,500 | 44,700 | 31,856 | 29.4 K to 31.9 K (+8.52 %) |
| Sep 06 2018 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Buy | M | 8.58 | 2,500 | 21,450 | 29,356 | 26.9 K to 29.4 K (+9.31 %) |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 14.47 | 12,000 | 173,640 | 33,675 | |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 9.97 | 1,044 | 10,409 | 39,982 | |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 255.01 | 12,000 | 3,060,082 | 103,300 | 115.3 K to 103.3 K (-10.41 %) |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 14.47 | 12,000 | 173,640 | 115,300 | 103.3 K to 115.3 K (+11.62 %) |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 9.97 | 1,044 | 10,409 | 103,300 | 102.3 K to 103.3 K (+1.02 %) |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Option Exercise | M | 21.92 | 469 | 10,280 | 0 | |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Option Exercise | M | 85.79 | 5,886 | 504,960 | 4,577 | |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Option Exercise | M | 74.42 | 5,985 | 445,404 | 1,931 | |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Option Exercise | M | 56.26 | 7,077 | 398,152 | 3,292 | |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Sell | S | 254.99 | 19,417 | 4,951,065 | 27,763 | 47.2 K to 27.8 K (-41.16 %) |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Buy | M | 85.79 | 5,886 | 504,960 | 47,180 | 41.3 K to 47.2 K (+14.25 %) |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Buy | M | 56.26 | 7,077 | 398,152 | 41,294 | 34.2 K to 41.3 K (+20.68 %) |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Buy | M | 74.42 | 5,985 | 445,404 | 34,217 | 28.2 K to 34.2 K (+21.20 %) |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Buy | M | 21.92 | 469 | 10,280 | 28,232 | 27.8 K to 28.2 K (+1.69 %) |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Option Exercise | M | 12.53 | 3,335 | 41,788 | 0 | |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Sell | S | 254.96 | 3,335 | 850,292 | 21,449 | 24.8 K to 21.4 K (-13.46 %) |
| Sep 05 2018 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Buy | M | 12.53 | 3,335 | 41,788 | 24,784 | 21.4 K to 24.8 K (+15.55 %) |